EUVIMEDEUVIMED entdecken
Crossref

Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs

Jianhua Cheng, Weiyan Xie, Yiyuan Chen, Yingxuan Sun, Lei Gong, Hongyun Wang, Chuzhong Li, Yazhuo Zhang

Drug Resistance Updates · 2024

DOI: 10.1016/j.drup.2024.101056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Jianhua Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Prolactinoma, Neuroendocrine Tumors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The treatment of dopamine agonists (DA) resistant prolactinomas remains a formidable challenge, as the mechanism of resistance is still unclear, and there are currently no viable alternative drug therapies available. This study seeks to investigate the mechanism of DA resistance in prolactinomas and identify new potentially effective drugs. METHODS: To explore the mechanism of DA resistance in prolactinomas, this study conducted transcriptome sequencing analysis on 27 cases of DA-resistant prolactinomas and 10 cases of sensitive prolactinomas. In addition, single-cell sequencing analysis was performed on 3 cases of DA-resistant prolactinomas and 3 cases of sensitive prolactinomas. Furthermore, to screen for potential therapeutic drugs, the study successfully established an organoids model for DA-resistant prolactinomas and screened 180 small molecule compounds using 8 organoids. The efficacy of the identified drugs was verified through various assays, including CCK-8, colony formation, CTG, and flow cytometry, and their mechanisms of action were confirmed through WB and IHC. The effectiveness of the identified drugs was evaluated both in vitro and in vivo. RESULTS: The results of transcriptome sequencing and single-cell sequencing analyses showed that DA resistance in prolactinomas is associated with the upregulation of the Focal Adhesion (FA) signaling pathway. Additionally, immunohistochemical validation revealed that FAK and Paxillin were significantly upregulated in DA-resistant prolactinomas. Screening of 180 small molecule compounds using 8 organoids identified Genistein as a potentially effective drug for DA-resistant prolactinomas. Experimental validation demonstrated that Genistein inhibited the proliferation of pituitary tumor cell lines and organoids and promoted apoptosis in pituitary tumor cells. Moreover, both the cell sequencing results and WB validation results of the drug-treated cells indicated that Genistein exerts its anti-tumor effect by inhibiting the FA pathway. In vivo, experiments also showed that Genistein can inhibit subcutaneous tumor formation. CONCLUSION: DA resistance in prolactinomas is associated with upregulation of the Focal Adhesion (FA) signaling pathway, and Genistein can exert its anti-tumor effect by inhibiting the expression of the FA pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsProlactinomaNeuroendocrine TumorsHumansDopamine AgonistsProlactinGenisteinDrug Resistance, Neoplasm

Stichwörter der Autor:innen

DA-resistant prolactinomasDrug screeningFocal adhesion pathwayGenisteinOrganoids

Substanzen

Dopamine AgonistsProlactinGenistein

Autor:innen und Institutionen

  • Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.
  • Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital affiliated with Capital Medical University, Beijing 100070, China; Beijing Institu…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cheng, J., Xie, W., Chen, Y., Sun, Y., Gong, L., Wang, H., Li, C., & Zhang, Y. (2024). Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101056

Vancouver

Cheng J, Xie W, Chen Y, Sun Y, Gong L, Wang H, et al. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101056

BibTeX
@article{Cheng2024,
  author = {Cheng, Jianhua and Xie, Weiyan and Chen, Yiyuan and Sun, Yingxuan and Gong, Lei and Wang, Hongyun and Li, Chuzhong and Zhang, Yazhuo},
  title = {Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs},
  journal = {Drug Resistance Updates},
  year = {2024},
  doi = {10.1016/j.drup.2024.101056}
}
Kostenlos starten →